DK1501848T3 - Syntese af låst nukleinsyrederivater - Google Patents

Syntese af låst nukleinsyrederivater

Info

Publication number
DK1501848T3
DK1501848T3 DK03718663T DK03718663T DK1501848T3 DK 1501848 T3 DK1501848 T3 DK 1501848T3 DK 03718663 T DK03718663 T DK 03718663T DK 03718663 T DK03718663 T DK 03718663T DK 1501848 T3 DK1501848 T3 DK 1501848T3
Authority
DK
Denmark
Prior art keywords
lna
synthesis
nucleic acid
acid derivatives
locked nucleic
Prior art date
Application number
DK03718663T
Other languages
English (en)
Inventor
Mads Detlef Sorensen
Jesper Wengel
Troels Koch
Signe M Christensen
Christoph Rosenbohm
Daniel Sejer Darwin C Pedersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of DK1501848T3 publication Critical patent/DK1501848T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
DK03718663T 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater DK1501848T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200200712 2002-05-08
DKPA200201214 2002-08-16
PCT/DK2003/000305 WO2003095467A1 (en) 2002-05-08 2003-05-08 Synthesis of locked nucleic acid derivatives

Publications (1)

Publication Number Publication Date
DK1501848T3 true DK1501848T3 (da) 2007-10-22

Family

ID=29421786

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03718663T DK1501848T3 (da) 2002-05-08 2003-05-08 Syntese af låst nukleinsyrederivater

Country Status (9)

Country Link
EP (1) EP1501848B1 (da)
JP (1) JP4476802B2 (da)
AT (1) ATE369375T1 (da)
AU (1) AU2003222743B2 (da)
CA (1) CA2484526C (da)
DE (1) DE60315444T2 (da)
DK (1) DK1501848T3 (da)
ES (1) ES2290448T3 (da)
WO (1) WO2003095467A1 (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE44779E1 (en) 1997-03-07 2014-02-25 Santaris Pharma A/S Bicyclonucleoside and oligonucleotide analogues
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
EP1569661B1 (en) 2002-11-18 2009-09-09 Santaris Pharma A/S Antisense design
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
AU2004221760B2 (en) 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
CA2550258A1 (en) 2003-12-23 2005-07-07 Santaris Pharma A/S Oligomeric compounds for the modulation of bcl-2
EA014097B1 (ru) 2004-11-09 2010-08-30 Сантарис Фарма А/С ОЛИГОНУКЛЕОТИДЫ ЗАМКНУТОЙ НУКЛЕИНОВОЙ КИСЛОТЫ (LNA) ДЛЯ МОДУЛИРОВАНИЯ ЭКСПРЕССИИ HIF-1a И ИХ ПРИМЕНЕНИЕ
EP1824975B9 (en) 2004-11-09 2011-04-20 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
US8071306B2 (en) 2005-01-25 2011-12-06 Merck Sharp & Dohme Corp. Methods for quantitating small RNA molecules
EP2002004B1 (en) 2006-03-23 2015-10-14 Roche Innovation Center Copenhagen A/S Small internally segmented interfering rna
JP5814505B2 (ja) 2006-04-03 2015-11-17 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
EP3431602A1 (en) 2006-04-03 2019-01-23 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2054415A1 (en) * 2006-07-14 2009-05-06 Santaris Pharma A/S Adenosine receptor antagonists
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
AU2008228243B2 (en) 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
ES2798758T3 (es) 2007-06-06 2020-12-14 Sarepta Therapeutics Inc Proteínas variantes de empalme her2 y her3 solubles, oligonucleótidos de cambio de empalme y su uso en el tratamiento de enfermedades
US8299237B2 (en) 2007-08-30 2012-10-30 Hadasit Medical Research Services & Development Ltd. Nucleic acid sequences comprising NF-κB binding site within O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter region and uses thereof for the treatment of cancer and immune-related disorders
CN101849008A (zh) 2007-09-19 2010-09-29 应用生物***有限公司 用于减少RNAi中的脱靶表型效应的siRNA的不依赖于序列的修饰形式和其稳定形式
AU2008306327B2 (en) 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
WO2010122538A1 (en) 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
ES2631458T3 (es) 2010-03-04 2017-08-31 Interna Technologies B.V. Molécula de ARNmi definida por su fuente y sus usos terapéuticos en el cáncer asociado a la EMT
CA2804599C (en) 2010-07-06 2023-01-31 Interna Technologies Bv Mirna and its diagnostic and therapeutic uses in diseases or conditions associated with melanoma, or in diseases or conditions associated with activated braf pathway
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
KR102108215B1 (ko) * 2011-07-21 2020-05-08 로디아 오퍼레이션스 구아 하이드록시프로필트리메틸암모늄 클로라이드 및 모발 처리용 조성물에서의 그 용도
ES2688619T3 (es) 2011-12-22 2018-11-05 Interna Technologies B.V. MiARN para tratar el cáncer de cabeza y de cuello
SG10201610936RA (en) 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014072357A1 (en) 2012-11-06 2014-05-15 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated b-raf pathway
EP2943570B1 (en) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitors of mirnas 221 and 222 for anti-tumor activity in multiple myeloma
US9428537B2 (en) 2013-03-15 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University tRNA derived small RNAs (tsRNAs) involved in cell viability
CN112263682A (zh) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
KR102620328B1 (ko) 2014-10-03 2024-01-02 콜드스프링하버러보러토리 핵 유전자 산출량의 표적화 증강
WO2016128583A2 (en) 2015-02-15 2016-08-18 Ribo Task Aps Acyl-amino-lna and/or hydrocarbyl-amino-lna oligonucleotides
TW201718618A (zh) * 2015-09-18 2017-06-01 田邊三菱製藥股份有限公司 架橋型核酸ＧｕＮＡ，其製造方法，及中間體化合物
KR20220105174A (ko) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG10201913477UA (en) 2016-04-29 2020-02-27 Univ Nanyang Tech G-quadruplex-containing antisense oligonucleotides
US20220354888A1 (en) 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
SG10202108375XA (en) 2017-08-25 2021-09-29 Stoke Therapeutics Inc Antisense oligomers for treatment of conditions and diseases
EP3704250A1 (en) 2017-11-03 2020-09-09 InteRNA Technologies B.V. Mirna molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
JP2021513508A (ja) 2018-02-12 2021-05-27 インテアールエヌエー テクノロジーズ ビー．ヴイ．ＩｎｔｅＲＮＡ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｂ．Ｖ． 抗がんマイクロｒｎａ及びその脂質製剤
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
US20230287410A1 (en) 2020-05-11 2023-09-14 Stoke Therapeutics, Inc. Opa1 antisense oligomers for treatment of conditions and diseases
IL304956A (en) 2021-02-12 2023-10-01 Merand Pharmaceuticals Inc Materials, compositions and methods for treating hypoxia and ischemia-related disorders
WO2022200632A1 (en) 2021-03-26 2022-09-29 Neumirna Therapeutics Aps Microrna-134 inhibitors
JP2024510665A (ja) 2021-03-26 2024-03-08 ニューミルナ セラピューティクス エーピーエス マイクロＲＮＡ－２７ｂ阻害剤
EP4347824A1 (en) 2021-06-04 2024-04-10 Neumirna Therapeutics ApS Antisense oligonucleotides targeting adenosine kinase
CA3229568A1 (en) 2021-08-17 2023-02-23 Korea Advanced Institute Of Science And Technology Antisense oligonucleotide targeting cav3.1 gene and uses thereof
CA3228833A1 (en) 2021-08-19 2023-02-23 Neumirna Therapeutics Aps Antisense oligonucleotides targeting adenosine kinase
EP4332239A1 (en) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-based assay for gastro-entero-pancreatic neuroendocrine tumor diagnosis and prognosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514348A (en) * 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
DE60119562T2 (de) * 2000-10-04 2007-05-10 Santaris Pharma A/S Verbesserte synthese von purin-blockierten nukleinsäure-analoga

Also Published As

Publication number Publication date
DE60315444D1 (en) 2007-09-20
WO2003095467A1 (en) 2003-11-20
AU2003222743A1 (en) 2003-11-11
ES2290448T3 (es) 2008-02-16
DE60315444T2 (de) 2008-04-30
EP1501848A1 (en) 2005-02-02
CA2484526C (en) 2009-10-13
ATE369375T1 (de) 2007-08-15
CA2484526A1 (en) 2003-11-20
EP1501848B1 (en) 2007-08-08
JP4476802B2 (ja) 2010-06-09
AU2003222743B2 (en) 2008-12-11
JP2005532319A (ja) 2005-10-27

Similar Documents

Publication Publication Date Title
DK1501848T3 (da) Syntese af låst nukleinsyrederivater
WO2007031548A3 (en) Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof
WO2007136817A3 (en) Substituted aryl piperidinylalkynyladenosines as a2ar agonists
TW200503724A (en) Novel pharmaceuticals
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
HK1088013A1 (en) Pyrimidine compounds having phosphonate groups as antiviral nucleotide analogs
WO2008141248A3 (en) Thiocarbon-protecting groups for rna synthesis
BRPI0516911A (pt) método para a preparação de um composto e composto de anilina
MY161575A (en) Mixture for the treatment of urea-containing fertilizers
GB0521508D0 (en) Organic compounds
TW200640912A (en) Novel processes for the preparation of a 2H-chromene
MY150490A (en) Improved process for producing hydrocyanic acid
GEP20125512B (en) Process for synthesis of agomelatin
BRPI0816911A8 (pt) Processo para preparação de 4-aminobut-2-enolidas
WO2009137444A3 (en) Cure accelerators for anaerobic curable compositions
WO2009137455A3 (en) Cure accelerators for anaerobic curable compositions
WO2007117591A3 (en) Total synthesis of salinosporamide a and analogs thereof
IL208290A0 (en) Process for the preparation of 10-deacetyl-bis-7, 10- trichloroacetylbaccatin iii
WO2007066158A3 (en) HIGH PURITY 17α-CYANOMETHYL-17β-HYDROXY-ESTRA-4,9-DIENE-3-ONE AND PROCESS FOR THE SYNTHESIS THEREOF
WO2005005389A3 (en) Malonamide derivatives
DK2046754T3 (da) Fremgangsmåde til fremstilling af alkylanilider ud fra halogenbenzenderivater
DK1877370T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
WO2011038152A3 (en) Toll-like receptor modulators and uses thereof
GB0327323D0 (en) Novel pharmaceuticals
WO2004002990A3 (en) Synthesis of purine derivatives